Ocrelizumab/hyaluronidase

Ocrelizumab/hyaluronidase, sold under the brand name Ocrevus Zunovo, is a fixed-dose combination medication used for the treatment of multiple sclerosis.^[1] It contains ocrelizumab, a recombinant humanized monoclonal antibody directed at CD20;^[1] and hyaluronidase (human recombinant), an endoglycosidase.^[1] It is taken by subcutaneous injection.^[1]

Ocrelizumab/hyaluronidase

Combination of
Ocrelizumab	Monoclonal antibody
Hyaluronidase	Endoglycosidase
Clinical data
Trade names	Ocrevus Zunovo
AHFS/Drugs.com	Ocrevus-zunovo
License data	US DailyMed: Ocrelizumab and hyaluronidase
Routes of administration	Subcutaneous
ATC code	None
Legal status
Legal status	US: ℞-only[1]

Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.^[2][3]

Medical uses

Ocrelizumab/hyaluronidase is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease;^[1] and primary progressive multiple sclerosis.^[1]